Literature DB >> 25795557

IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?

Luis Masana1, Juan Pedro-Botet2, Fernando Civeira3.   

Abstract

Entities:  

Keywords:  Ezetimibe; High-intensity cholesterol-lowering therapy; IMPROVE-IT

Mesh：

Substances：

Year:  2015        PMID： 25795557     DOI： 10.1016/j.atherosclerosis.2015.03.002

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  7 in total

1.  ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Gualtiero Ricciardi; Simona Giampaoli; Aldo Pietro Maggioni; Maurizio Averna; Maria Stella Graziani; Ferruccio Ceriotti; Alessandro Mugelli; Francesco Rossi; Gerardo Medea; Damiano Parretti; Maurizio Giuseppe Abrignani; Marcello Arca; Pasquale Perrone Filardi; Francesco Perticone; Alberico Catapano; Raffaele Griffo; Federico Nardi; Carmine Riccio; Andrea Di Lenarda; Marino Scherillo; Nicoletta Musacchio; Antonio Vittorio Panno; Giovanni Battista Zito; Mauro Campanini; Leonardo Bolognese; Pompilio Massimo Faggiano; Giuseppe Musumeci; Enrico Pusineri; Marcello Ciaccio; Enzo Bonora; Giorgio Cantelli Forti; Maria Pia Ruggieri; Claudio Cricelli; Francesco Romeo; Roberto Ferrari; Attilio Maseri
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 2.  Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy.

Authors:  Lluís Masana; Daiana Ibarretxe; Núria Plana
Journal:  Curr Cardiol Rep       Date:  2020-06-19       Impact factor: 2.931

Review 3.  Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?

Authors:  Pier Luigi Temporelli; Marcello Arca; Laura D'Erasmo; Raffaele De Caterina
Journal:  J Clin Med       Date:  2021-02-22       Impact factor: 4.241

4.  Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks.

Authors:  Yu-Cheng Kao; Tien-Hsing Chen; Chi-Hung Liu; Jawl-Shan Hwang; Ching-Chung Hsiao; Yu-Sheng Lin; Chun-Tai Mao; Ming-Jui Hung; Yan-Rong Li
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

5.  Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank.

Authors:  Andrew R English; Bodhayan Prasad; Declan H McGuigan; Geraldine Horigan; Maurice O'Kane; Anthony J Bjourson; Priyank Shukla; Catriona Kelly; Paula L McClean
Journal:  Endocrinol Diabetes Metab       Date:  2022-03-04

6.  An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome.

Authors:  Sonia Ruiz-Bustillo; Neus Badosa; Ignacio Cabrera-Aguilera; Consol Ivern; Marc Llagostera; Diana Mojón; Miren Vicente; Núria Ribas; Lluis Recasens; Julio Martí-Almor; Mercè Cladellas; Núria Farré
Journal:  Front Cardiovasc Med       Date:  2022-07-26

Review 7.  Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges.

Authors:  Chris Packard; M John Chapman; Mahendra Sibartie; Ulrich Laufs; Luis Masana
Journal:  Heart       Date:  2021-04-01       Impact factor: 5.994
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.